Floatz logo

LENVATINIB

Rectal Cancer

H. Lee Moffitt Cancer Center and Research InstituteSmall moleculePhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

114 Active assets in the Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB

View all 50 →

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →